Understanding the reasoning behind deep learning model predictions is crucial in cheminformatics and drug discovery, where molecular design determines their properties. However, current evaluation frameworks for Explainable AI (XAI) in this domain often rely on artificial datasets or simplified tasks, employing data-derived metrics that fail to capture the complexity of real-world scenarios and lack a direct link to explanation faithfulness. To address this, we introduce B-XAIC, a novel benchmark constructed from real-world molecular data and diverse tasks with known ground-truth rationales for assigned labels. Through a comprehensive evaluation using B-XAIC, we reveal limitations of existing XAI methods for Graph Neural Networks (GNNs) in the molecular domain. This benchmark provides a valuable resource for gaining deeper insights into the faithfulness of XAI, facilitating the development of more reliable and interpretable models.
Accurately predicting drug-target interactions (DTIs) is pivotal for advancing drug discovery and target validation techniques. While machine learning approaches including those that are based on Graph Neural Networks (GNN) have achieved notable success in DTI prediction, many of them have difficulties in effectively integrating the diverse features of drugs, targets and their interactions. To address this limitation, we introduce a novel framework to take advantage of the power of both transductive learning and inductive learning so that features at molecular level and drug-target interaction network level can be exploited. Within this framework is a GNN-based model called Graph-in-Graph (GiG) that represents graphs of drug and target molecular structures as meta-nodes in a drug-target interaction graph, enabling a detailed exploration of their intricate relationships. To evaluate the proposed model, we have compiled a special benchmark comprising drug SMILES, protein sequences, and their interaction data, which is interesting in its own right. Our experimental results demonstrate that the GiG model significantly outperforms existing approaches across all evaluation metrics, highlighting the benefits of integrating different learning paradigms and interaction data.
Scientific databases aggregate vast amounts of quantitative data alongside descriptive text. In biochemistry, molecule screening assays evaluate the functional responses of candidate molecules against disease targets. Unstructured text that describes the biological mechanisms through which these targets operate, experimental screening protocols, and other attributes of assays offer rich information for new drug discovery campaigns but has been untapped because of that unstructured format. We present Assay2Mol, a large language model-based workflow that can capitalize on the vast existing biochemical screening assays for early-stage drug discovery. Assay2Mol retrieves existing assay records involving targets similar to the new target and generates candidate molecules using in-context learning with the retrieved assay screening data. Assay2Mol outperforms recent machine learning approaches that generate candidate ligand molecules for target protein structures, while also promoting more synthesizable molecule generation.
We present a modular framework powered by large language models (LLMs) that automates and streamlines key tasks across the early-stage computational drug discovery pipeline. By combining LLM reasoning with domain-specific tools, the framework performs biomedical data retrieval, domain-specific question answering, molecular generation, property prediction, property-aware molecular refinement, and 3D protein-ligand structure generation. In a case study targeting BCL-2 in lymphocytic leukemia, the agent autonomously retrieved relevant biomolecular information-including FASTA sequences, SMILES representations, and literature-and answered mechanistic questions with improved contextual accuracy over standard LLMs. It then generated chemically diverse seed molecules and predicted 67 ADMET-related properties, which guided iterative molecular refinement. Across two refinement rounds, the number of molecules with QED > 0.6 increased from 34 to 55, and those passing at least four out of five empirical drug-likeness rules rose from 29 to 52, within a pool of 194 molecules. The framework also employed Boltz-2 to generate 3D protein-ligand complexes and provide rapid binding affinity estimates for candidate compounds. These results demonstrate that the approach effectively supports molecular screening, prioritization, and structure evaluation. Its modular design enables flexible integration of evolving tools and models, providing a scalable foundation for AI-assisted therapeutic discovery.
Graph learning has rapidly evolved into a critical subfield of machine learning and artificial intelligence (AI). Its development began with early graph-theoretic methods, gaining significant momentum with the advent of graph neural networks (GNNs). Over the past decade, progress in scalable architectures, dynamic graph modeling, multimodal learning, generative AI, explainable AI (XAI), and responsible AI has broadened the applicability of graph learning to various challenging environments. Graph learning is significant due to its ability to model complex, non-Euclidean relationships that traditional machine learning struggles to capture, thus better supporting real-world applications ranging from drug discovery and fraud detection to recommender systems and scientific reasoning. However, challenges like scalability, generalization, heterogeneity, interpretability, and trustworthiness must be addressed to unlock its full potential. This survey provides a comprehensive introduction to graph learning, focusing on key dimensions including scalable, temporal, multimodal, generative, explainable, and responsible graph learning. We review state-of-the-art techniques for efficiently handling large-scale graphs, capturing dynamic temporal dependencies, integrating heterogeneous data modalities, generating novel graph samples, and enhancing interpretability to foster trust and transparency. We also explore ethical considerations, such as privacy and fairness, to ensure responsible deployment of graph learning models. Additionally, we identify and discuss emerging topics, highlighting recent integration of graph learning and other AI paradigms and offering insights into future directions. This survey serves as a valuable resource for researchers and practitioners seeking to navigate the rapidly evolving landscape of graph learning.
Large-language models (LLMs) and agentic systems present exciting opportunities to accelerate drug discovery and design. In this study, we critically examine the modularity of LLM-based agentic systems for drug discovery, i.e., whether parts of the agentic system such as the LLM are interchangeable, a topic that has received limited attention in drug discovery applications. We compare the performance of different large language models (LLMs) and the effectiveness of tool-calling agents versus code-generating agents in this domain. Our case study, comparing performance in orchestrating tools for chemistry and drug discovery using an LLM-as-a-judge score, shows that Claude-3.5-Sonnet, Claude-3.7-Sonnet and GPT-4o outperform alternative language models such as Llama-3.1-8B, Llama-3.1-70B, GPT-3.5-Turbo, and Nova-Micro. Although we confirm that code-generating agents outperform the tool-calling ones on average, we show that this is highly question and model dependent. Furthermore, the impact of replacing system prompts is dependent on the specific question asked and the model used, underscoring that -- even in this particular domain -- one cannot just replace language models without considering prompt re-engineering. Our study highlights the necessity of further research into the modularity of agentic systems to enable the development of stable and scalable solutions for real-world problems.
In many real-world applications, evaluating the goodness of instances is often costly and time-consuming, e.g., human feedback and physics simulations, in contrast to proposing new instances. In particular, this is even more critical in reinforcement learning, as new interactions with the environment (i.e., new instances) need to be evaluated to provide a reward signal to learn from. As sufficient exploration is crucial, learning from a diverse mini-batch can have a large impact and help mitigate mode collapse. In this paper, we introduce diverse mini-batch selection for reinforcement learning and propose to use determinantal point processes for this task. We study this framework in the context of a real-world problem, namely drug discovery. We experimentally study how our proposed framework can improve the effectiveness of chemical exploration in de novo drug design, where finding diverse and high-quality solutions is essential. We conduct a comprehensive evaluation with three well-established molecular generation oracles over numerous generative steps. Our experiments conclude that our diverse mini-batch selection framework can substantially improve the diversity of the solutions, while still obtaining solutions of high quality. In drug discovery, such outcome can potentially lead to fulfilling unmet medication needs faster.
Sampling low-energy molecular conformations, spatial arrangements of atoms in a molecule, is a critical task for many different calculations performed in the drug discovery and optimization process. Numerous specialized equivariant networks have been designed to generate molecular conformations from 2D molecular graphs. Recently, non-equivariant transformer models have emerged as a viable alternative due to their capability to scale to improve generalization. However, the concern has been that non-equivariant models require a large model size to compensate the lack of equivariant bias. In this paper, we demonstrate that a well-chosen positional encoding effectively addresses these size limitations. A standard transformer model incorporating relative positional encoding for molecular graphs when scaled to 25 million parameters surpasses the current state-of-the-art non-equivariant base model with 64 million parameters on the GEOM-DRUGS benchmark. We implemented relative positional encoding as a negative attention bias that linearly increases with the shortest path distances between graph nodes at varying slopes for different attention heads, similar to ALiBi, a widely adopted relative positional encoding technique in the NLP domain. This architecture has the potential to serve as a foundation for a novel class of generative models for molecular conformations.
Simultaneously optimizing molecules against multiple therapeutic targets remains a profound challenge in drug discovery, particularly due to sparse rewards and conflicting design constraints. We propose a structured active learning (AL) paradigm integrating a sequence-to-sequence (Seq2Seq) variational autoencoder (VAE) into iterative loops designed to balance chemical diversity, molecular quality, and multi-target affinity. Our method alternates between expanding chemically feasible regions of latent space and progressively constraining molecules based on increasingly stringent multi-target docking thresholds. In a proof-of-concept study targeting three related coronavirus main proteases (SARS-CoV-2, SARS-CoV, MERS-CoV), our approach efficiently generated a structurally diverse set of pan-inhibitor candidates. We demonstrate that careful timing and strategic placement of chemical filters within this active learning pipeline markedly enhance exploration of beneficial chemical space, transforming the sparse-reward, multi-objective drug design problem into an accessible computational task. Our framework thus provides a generalizable roadmap for efficiently navigating complex polypharmacological landscapes.
Quantitative Structure-Activity Relationship (QSAR) modeling is a cornerstone of computational drug discovery. This research demonstrates the successful application of a Quantum Multiple Kernel Learning (QMKL) framework to enhance QSAR classification, showing a notable performance improvement over classical methods. We apply this methodology to a dataset for identifying DYRK1A kinase inhibitors. The workflow involves converting SMILES representations into numerical molecular descriptors, reducing dimensionality via Principal Component Analysis (PCA), and employing a Support Vector Machine (SVM) trained on an optimized combination of multiple quantum and classical kernels. By benchmarking the QMKL-SVM against a classical Gradient Boosting model, we show that the quantum-enhanced approach achieves a superior AUC score, highlighting its potential to provide a quantum advantage in challenging cheminformatics classification tasks.
The exponential growth of scientific literature challenges researchers extracting and synthesizing knowledge. Traditional search engines return many sources without direct, detailed answers, while general-purpose LLMs may offer concise responses that lack depth or omit current information. LLMs with search capabilities are also limited by context window, yielding short, incomplete answers. This paper introduces WISE (Workflow for Intelligent Scientific Knowledge Extraction), a system addressing these limits by using a structured workflow to extract, refine, and rank query-specific knowledge. WISE uses an LLM-powered, tree-based architecture to refine data, focusing on query-aligned, context-aware, and non-redundant information. Dynamic scoring and ranking prioritize unique contributions from each source, and adaptive stopping criteria minimize processing overhead. WISE delivers detailed, organized answers by systematically exploring and synthesizing knowledge from diverse sources. Experiments on HBB gene-associated diseases demonstrate WISE reduces processed text by over 80% while achieving significantly higher recall over baselines like search engines and other LLM-based approaches. ROUGE and BLEU metrics reveal WISE's output is more unique than other systems, and a novel level-based metric shows it provides more in-depth information. We also explore how the WISE workflow can be adapted for diverse domains like drug discovery, material science, and social science, enabling efficient knowledge extraction and synthesis from unstructured scientific papers and web sources.
A widely recognized limitation of molecular prediction models is their reliance on structures observed in the training data, resulting in poor generalization to out-of-distribution compounds. Yet in drug discovery, the compounds most critical for advancing research often lie beyond the training set, making the bias toward the training data particularly problematic. This mismatch introduces substantial covariate shift, under which standard deep learning models produce unstable and inaccurate predictions. Furthermore, the scarcity of labeled data, stemming from the onerous and costly nature of experimental validation, further exacerbates the difficulty of achieving reliable generalization. To address these limitations, we propose a novel meta-learning-based approach that leverages unlabeled data to interpolate between in-distribution (ID) and out-of-distribution (OOD) data, enabling the model to meta-learn how to generalize beyond the training distribution. We demonstrate significant performance gains over state-of-the-art methods on challenging real-world datasets that exhibit substantial covariate shift.
In the past decades, machine learning with Empirical Risk Minimization (ERM) has demonstrated great capability in learning and exploiting the statistical patterns from data, or even surpassing humans. Despite the success, ERM avoids the modeling of causality the way of understanding and handling changes, which is fundamental to human intelligence. When deploying models beyond the training environment, distribution shifts are everywhere. For example, an autopilot system often needs to deal with new weather conditions that have not been seen during training, An Al-aided drug discovery system needs to predict the biochemical properties of molecules with respect to new viruses such as COVID-19. It renders the problem of Out-of-Distribution (OOD) generalization challenging to conventional machine learning. In this thesis, we investigate how to incorporate and realize the causality for broader tasks in modern machine learning. In particular, we exploit the invariance implied by the principle of independent causal mechanisms (ICM), that is, the causal mechanisms generating the effects from causes do not inform or influence each other. Therefore, the conditional distribution between the target variable given its causes is invariant under distribution shifts. With the causal invariance principle, we first instantiate it to graphs -- a general data structure ubiquitous in many real-world industry and scientific applications, such as financial networks and molecules. Then, we shall see how learning the causality benefits many of the desirable properties of modern machine learning, in terms of (i) OOD generalization capability; (ii) interpretability; and (iii) robustness to adversarial attacks. Realizing the causality in machine learning, on the other hand, raises a dilemma for optimization in conventional machine learning, as it often contradicts the objective of ERM...
Bayesian optimization of function networks (BOFN) is a framework for optimizing expensive-to-evaluate objective functions structured as networks, where some nodes' outputs serve as inputs for others. Many real-world applications, such as manufacturing and drug discovery, involve function networks with additional properties - nodes that can be evaluated independently and incur varying costs. A recent BOFN variant, p-KGFN, leverages this structure and enables cost-aware partial evaluations, selectively querying only a subset of nodes at each iteration. p-KGFN reduces the number of expensive objective function evaluations needed but has a large computational overhead: choosing where to evaluate requires optimizing a nested Monte Carlo-based acquisition function for each node in the network. To address this, we propose an accelerated p-KGFN algorithm that reduces computational overhead with only a modest loss in query efficiency. Key to our approach is generation of node-specific candidate inputs for each node in the network via one inexpensive global Monte Carlo simulation. Numerical experiments show that our method maintains competitive query efficiency while achieving up to a 16x speedup over the original p-KGFN algorithm.
Sampling physically valid ligand-binding poses remains a major challenge in molecular docking, particularly for unseen or structurally diverse targets. We introduce PocketVina, a fast and memory-efficient, search-based docking framework that combines pocket prediction with systematic multi-pocket exploration. We evaluate PocketVina across four established benchmarks--PDBbind2020 (timesplit and unseen), DockGen, Astex, and PoseBusters--and observe consistently strong performance in sampling physically valid docking poses. PocketVina achieves state-of-the-art performance when jointly considering ligand RMSD and physical validity (PB-valid), while remaining competitive with deep learning-based approaches in terms of RMSD alone, particularly on structurally diverse and previously unseen targets. PocketVina also maintains state-of-the-art physically valid docking accuracy across ligands with varying degrees of flexibility. We further introduce TargetDock-AI, a benchmarking dataset we curated, consisting of over 500000 protein-ligand pairs, and a partition of the dataset labeled with PubChem activity annotations. On this large-scale dataset, PocketVina successfully discriminates active from inactive targets, outperforming a deep learning baseline while requiring significantly less GPU memory and runtime. PocketVina offers a robust and scalable docking strategy that requires no task-specific training and runs efficiently on standard GPUs, making it well-suited for high-throughput virtual screening and structure-based drug discovery.
Breakthroughs in high-accuracy protein structure prediction, such as AlphaFold, have established receptor-based molecule design as a critical driver for rapid early-phase drug discovery. However, most approaches still struggle to balance pocket-specific geometric fit with strict valence and synthetic constraints. To resolve this trade-off, a Retrieval-Enhanced Aligned Diffusion termed READ is introduced, which is the first to merge molecular Retrieval-Augmented Generation with an SE(3)-equivariant diffusion model. Specifically, a contrastively pre-trained encoder aligns atom-level representations during training, then retrieves graph embeddings of pocket-matched scaffolds to guide each reverse-diffusion step at inference. This single mechanism can inject real-world chemical priors exactly where needed, producing valid, diverse, and shape-complementary ligands. Experimental results demonstrate that READ can achieve very competitive performance in CBGBench, surpassing state-of-the-art generative models and even native ligands. That suggests retrieval and diffusion can be co-optimized for faster, more reliable structure-based drug design.
Graph generation has emerged as a critical task in fields ranging from molecule design to drug discovery. Contemporary approaches, notably diffusion and flow-based models, have achieved solid graph generative performance through constructing a probability path that interpolates between a reference distribution and the data distribution. However, these methods typically model the evolution of individual nodes and edges independently and use linear interpolations to build the path assuming that the data lie in Euclidean space. We show that this is suboptimal given the intrinsic non-Euclidean structure and interconnected patterns of graphs, and it poses risks to the sampling convergence. To build a better probability path, we model the joint evolution of the nodes and edges by representing graphs as connected systems parameterized by Markov random fields (MRF). We then leverage the optimal transport displacement between MRF objects to design the probability path for graph generation. Based on this, we introduce BWFlow, a flow-matching framework for graph generation that respects the underlying geometry of graphs and provides smooth velocities in the probability path. The novel framework can be adapted to both continuous and discrete flow-matching algorithms. Experimental evaluations in plain graph generation and 2D/3D molecule generation validate the effectiveness of BWFlow in graph generation with competitive performance, stable training, and guaranteed sampling convergence.
Image-based cell profiling aims to create informative representations of cell images. This technique is critical in drug discovery and has greatly advanced with recent improvements in computer vision. Inspired by recent developments in non-contrastive Self-Supervised Learning (SSL), this paper provides an initial exploration into training a generalizable feature extractor for cell images using such methods. However, there are two major challenges: 1) There is a large difference between the distributions of cell images and natural images, causing the view-generation process in existing SSL methods to fail; and 2) Unlike typical scenarios where each representation is based on a single image, cell profiling often involves multiple input images, making it difficult to effectively combine all available information. To overcome these challenges, we propose SSLProfiler, a non-contrastive SSL framework specifically designed for cell profiling. We introduce specialized data augmentation and representation post-processing methods tailored to cell images, which effectively address the issues mentioned above and result in a robust feature extractor. With these improvements, SSLProfiler won the Cell Line Transferability challenge at CVPR 2025.
In this paper, we review recent developments and the role of Graph Neural Networks (GNNs) in computational drug discovery, including molecule generation, molecular property prediction, and drug-drug interaction prediction. By summarizing the most recent developments in this area, we underscore the capabilities of GNNs to comprehend intricate molecular patterns, while exploring both their current and prospective applications. We initiate our discussion by examining various molecular representations, followed by detailed discussions and categorization of existing GNN models based on their input types and downstream application tasks. We also collect a list of commonly used benchmark datasets for a variety of applications. We conclude the paper with brief discussions and summarize common trends in this important research area.
Virtual screening (VS) is a critical component of modern drug discovery, yet most existing methods--whether physics-based or deep learning-based--are developed around holo protein structures with known ligand-bound pockets. Consequently, their performance degrades significantly on apo or predicted structures such as those from AlphaFold2, which are more representative of real-world early-stage drug discovery, where pocket information is often missing. In this paper, we introduce an alignment-and-aggregation framework to enable accurate virtual screening under structural uncertainty. Our method comprises two core components: (1) a tri-modal contrastive learning module that aligns representations of the ligand, the holo pocket, and cavities detected from structures, thereby enhancing robustness to pocket localization error; and (2) a cross-attention based adapter for dynamically aggregating candidate binding sites, enabling the model to learn from activity data even without precise pocket annotations. We evaluated our method on a newly curated benchmark of apo structures, where it significantly outperforms state-of-the-art methods in blind apo setting, improving the early enrichment factor (EF1%) from 11.75 to 37.19. Notably, it also maintains strong performance on holo structures. These results demonstrate the promise of our approach in advancing first-in-class drug discovery, particularly in scenarios lacking experimentally resolved protein-ligand complexes.